🔎 Trials Near Me

Utama › Leukemia Mieloid Fase Kronik › California

Kajian klinikal Leukemia Mieloid Fase Kronik di California

5 kajian untuk Leukemia Mieloid Fase Kronik sedang mencari peserta di lokasi di California.

Teks kajian rasmi (Bahasa Inggeris)

Study of Olverembatinib (HQP1351) in Patients With CML-CP

  • Ascentage Investigative Site #1062, Duarte
  • Ascentage Investigative Site #1099, Irvine
  • Ascentage Investigative Site #1075, La Jolla
  • dan 4 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06423911

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

  • City of Hope Medical Center, Duarte
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 75 · Semua jantina · Dikemas kini 28 Jul 2026 · NCT07020533

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  • Stockton Hematology Oncology Medical Group Inc, Stockton
  • Lundquist Inst BioMed at Harbor, Torrance
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 100 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT07091019

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

  • Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Mac 2026 · NCT06229860

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

  • UC Irvine Health, Orange
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jan 2026 · NCT06163430

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.